Survey Study About Endoscopy During COVID-19 Pandemic for IBD Doctors

July 19, 2021 updated by: Second Affiliated Hospital, School of Medicine, Zhejiang University

Patterns of Endoscopy During COVID-19 Pandemic: a Global Survey of Interventional Inflammatory Bowel Disease Practice

Performance of diagnostic or therapeutic endoscopic procedures in inflammatory bowel disease (IBD) patients can be challenging during a viral pandemic; the main concerns being the safety and protection of patients and health care providers (HCP). The aim of this study is to identify endoscopic practice patterns and outcomes of IBD and coronavirus disease 19 (COVID-19) with a worldwide survey of HCP.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The 20-item survey questionnaire was sent to physician members of the American Society for Gastrointestinal Endoscopy Special Interest Group in Interventional IBD, Chinese IBD Society Endoscopy Interest Group, and the China Crohn's and Colitis Foundation. The data of the survey was collected and analyzed.

Study Type

Observational

Enrollment (Actual)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Hangzhou
      • Zhengzhou, Hangzhou, China, 310000
        • Second Affiliated Hospital Zhejiang University School of Medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

The content of survey included: The number of procedures, the indication of endoscopy, the number of patients with IBD diagnosed Covid-19, and the influence of the epidemic situation on the diagnosis and treatment of IBD.

Description

Inclusion Criteria:

  1. Doctors who are involved in the endoscopic treatment of IBD patients;
  2. The endoscopist reads and signs an informed consent online. -

Exclusion Criteria:

  1. Doctors who are not involved in the endoscopic treatment of IBD patients
  2. Doctors who need the help of an agent, a witness, or someone else who can not complete the questionnaire independently.
  3. Other conditions that the researchers considered unsuitable for inclusion or influenced the participants'ability to complete the study.-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Other
  • Time Perspectives: Retrospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
one group that is IBD endoscopist who perform the endoscopy for IBD patients
Complete the questionnaire online
Other: observation
IBD doctors who perform the endoscopy perform the questionnaire
Other Names:
  • endoscopy with no drug

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The influence of covid-19 pandemic on endoscopic practice by IBD endoscopist
Time Frame: 1 week
The incidence of scheduled IBD endoscopies were postponed or cancelled due to the pandemic.
1 week

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The incidence of COVID19 in IBD patients who underwent endoscopy
Time Frame: 1 week
The percentage of IBD patients who underwent endoscopy since the outbreak was tested positive for COVID 19
1 week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Investigators

  • Principal Investigator: Yan Chen, 浙江大学医学院附属第二医院

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 15, 2021

Primary Completion (Actual)

July 15, 2021

Study Completion (Actual)

July 15, 2021

Study Registration Dates

First Submitted

July 15, 2021

First Submitted That Met QC Criteria

July 19, 2021

First Posted (Actual)

July 21, 2021

Study Record Updates

Last Update Posted (Actual)

July 21, 2021

Last Update Submitted That Met QC Criteria

July 19, 2021

Last Verified

April 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • I2020001357

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Yes

IPD Plan Description

The result of questionnaire can be shared

IPD Sharing Time Frame

now is available

IPD Sharing Access Criteria

All the doctors

IPD Sharing Supporting Information Type

  • Study Protocol

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Inflammatory Bowel Diseases

Clinical Trials on observation

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe